These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 20377145

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dose escalation pharmacokinetics of intranasal scopolamine gel formulation.
    Wu L, Boyd JL, Daniels V, Wang Z, Chow DS, Putcha L.
    J Clin Pharmacol; 2015 Feb; 55(2):195-203. PubMed ID: 25187210
    [Abstract] [Full Text] [Related]

  • 5. Various anti-motion sickness drugs and core body temperature changes.
    Cheung B, Nakashima AM, Hofer KD.
    Aviat Space Environ Med; 2011 Apr; 82(4):409-15. PubMed ID: 21485398
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E, Offer-Ohlsen D, Lillevold PE, Sandvik L.
    Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
    [Abstract] [Full Text] [Related]

  • 9. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM, Schmitt LG, McGuire J, Shaw JE, Trobough G.
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A, Knepton J, Shaw J.
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [Abstract] [Full Text] [Related]

  • 13. Transdermal scopolamine in motion sickness.
    Cronin CM, Sallan SE, Wolfe L.
    Pharmacotherapy; 1982 Oct; 2(1):29-31. PubMed ID: 6927209
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anticholinergic Versus Antihistaminic Treatment for Simulator Sickness Prevention.
    Ben-Ari O, Sarfati S, Gordon B, Assa A, Nakdimon I.
    J Clin Pharmacol; 2023 Oct; 63(10):1119-1125. PubMed ID: 37491788
    [Abstract] [Full Text] [Related]

  • 17. Treatment of motion sickness in parabolic flight with buccal scopolamine.
    Norfleet WT, Degioanni JJ, Calkins DS, Reschke MF, Bungo MW, Kutyna FA, Homick JL.
    Aviat Space Environ Med; 1992 Jan; 63(1):46-51. PubMed ID: 1550533
    [Abstract] [Full Text] [Related]

  • 18. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME, Royal JW, Shaw JE, Schmitt LG.
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [Abstract] [Full Text] [Related]

  • 19. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET, Zhou DR, He LH.
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [Abstract] [Full Text] [Related]

  • 20. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
    Golding JF, Wesnes KA, Leaker BR.
    Br J Clin Pharmacol; 2018 Jul; 84(7):1535-1543. PubMed ID: 29522648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.